Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Oct 1;36(5):385-393.
doi: 10.1097/QCO.0000000000000948. Epub 2023 Jul 18.

mRNA vaccines against respiratory viruses

Jennifer A Whitaker  1   2 , Hana M El Sahly  1   2 , C Mary Healy  3
Affiliations
Review

mRNA vaccines against respiratory viruses

Jennifer A Whitaker et al. Curr Opin Infect Dis. .

Abstract

Purpose of review: The successes of the coronavirus disease 2019 (COVID-19) mRNA vaccines have accelerated the development of mRNA vaccines against other respiratory pathogens. The aim of this review is to highlight COVID-19 mRNA vaccine advances and provide an update on the progress of mRNA vaccine development against other respiratory pathogens.

Recent findings: The COVID-19 mRNA vaccines demonstrated effectiveness in preventing severe COVID-19 and death. H7N9 and H10N8 avian influenza mRNA vaccines have demonstrated safety and immunogenicity in phase 1 clinical trials. Numerous seasonal influenza mRNA vaccines are in phase 1-3 clinical trials. Respiratory syncytial virus (RSV) mRNA vaccines have progressed to phase 2-3 clinical trials in adults and a phase 1 clinical trial in children. A combined human metapneumovirus and parainfluenza-3 mRNA vaccines was found to be well tolerated and immunogenic in a phase 1 trial among adults and trials are being conducted among children. Clinical trials of mRNA vaccines combining antigens from multiple respiratory viruses are underway.

Summary: The development of mRNA vaccines against respiratory viruses has progressed rapidly in recent years. Promising vaccine candidates are moving through the clinical development pathway to test their efficacy in preventing disease against respiratory viral pathogens.

PubMed Disclaimer

References

    1. Szabo GT, Mahiny AJ, Vlatkovic I. COVID-19 mRNA vaccines: platforms and current developments. Mol Ther 2022; 30:1850–1868.
    1. Rzymski P, Szuster-Ciesielska A, Dzieciatkowski T, et al. mRNA vaccines: the future of prevention of viral infections? J Med Virol 2023; 95:e28572.
    1. Akamine CM, El Sahly HM. Messenger ribonucleic acid vaccines for severe acute respiratory syndrome coronavirus-2: a review. Transl Res 2022; 242:1–19.
    1. Chalkias S, Harper C, Vrbicky K, et al. A bivalent Omicron-containing booster vaccine against Covid-19. N Engl J Med 2022; 387:1279–1291.
    1. Winokur P, Gayed J, Fitz-Patrick D, et al. Bivalent Omicron BA.1-adapted BNT162b2 booster in adults older than 55 years. N Engl J Med 2023; 388:214–227.